
Staging before the plan
Core/excision biopsy with immunophenotyping, PET-CT and marrow assessment define subtype and stage.
Treatment modalities we may use
- 01R-CHOP and subtype-specific chemoimmunotherapy
- 02Targeted agents and CAR-T for relapsed disease
- 03Ablation of a PET-positive residual mass
- 04Embolization of rare bulky vascular disease
How the pathway is sequenced
Systemic therapy leads; end-of-treatment PET decides whether a residual site is scar or active disease — a solitary active residual can be ablated or irradiated, sparing patients further systemic chemotherapy.
At Guangzhou St. Stamford Hospital every pathway is decided by a multidisciplinary tumour board: interventional radiologists, medical oncologists, surgeons and imaging specialists review your actual scans together. Send us your imaging and pathology before you travel and receive a written, stage-specific treatment plan in English.
Still have questions?
Reach our care team for personalized guidance on diagnosis, treatment, and insurance.
